Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs.
about
Acetaminophen-induced Liver Injury: from Animal Models to HumansPharmacogenomics of adverse drug reactionsSignal transducer and activator of transcription 4 in liver diseasesPathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives.Selected ABCB1, ABCB4 and ABCC2 polymorphisms do not enhance the risk of drug-induced hepatotoxicity in a Spanish cohortAnalysis of IL-6, STAT3 and HSPA1L gene polymorphisms in anti-tuberculosis drug-induced hepatitis in a nested case-control studyPatient-specific hepatocyte-like cells derived from induced pluripotent stem cells model pazopanib-mediated hepatotoxicityDrug-induced liver injury: recent advances in diagnosis and risk assessment.Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review.Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome.Clinical Features and Outcomes of Complementary and Alternative Medicine Induced Acute Liver Failure and Injury.Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury.Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network.Serum acute phase reactants hallmark healthy individuals at risk for acetaminophen-induced liver injury.Genome-wide association and replication study of anti-tuberculosis drugs-induced liver toxicity.Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here?Amoxicillin-Clavulanate-Induced Liver Injury.Liver injury from nonsteroidal anti-inflammatory drugs in the United States.A collaborative approach to developing an electronic health record phenotyping algorithm for drug-induced liver injury.Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis.Toward predictive models for drug-induced liver injury in humans: are we there yet?Pharmacogenovigilance: a pharmacogenomics pharmacovigilance program.Risk factors for severe or fatal drug-induced liver injury from amoxicillin-clavulanic acid.Effect of drug transporter pharmacogenetics on cholestasis.Key factors of susceptibility to anti-tuberculosis drug-induced hepatotoxicity.The chemical, genetic and immunological basis of idiosyncratic drug-induced liver injury.Emerging hepatotoxicity biomarkers and their potential to improve understanding and management of drug-induced liver injuryRecent advances in biomarkers and therapeutic interventions for hepatic drug safety - false dawn or new horizon?Drug metabolism and liver disease: a drug-gene-environment interaction.Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.Are Polymorphisms in Genes Relevant to Drug Disposition Predictors of Susceptibility to Drug-Induced Liver Injury?Genome-Wide Association Studies for Idiosyncratic Drug-Induced Hepatotoxicity: Looking Back-Looking Forward to Next-Generation Innovation.Pharmacogenomics of CYP2C9: Functional and Clinical Considerations.Characterization of Drug-Specific Signaling Between Primary Human Hepatocytes and Immune Cells.The Role of Public-Private Partnerships in Catalyzing the Critical Path.N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group
P2860
Q26781944-9B918B5B-1A0C-42AF-BB03-188E2BAD4910Q27015820-5EBB31D9-50CB-42FF-A721-7B458AA8D60BQ27016571-0D8AD3C2-CCBA-428C-82D5-CBFA27C1090AQ27690772-336C7313-D585-465A-950D-626E5D259B26Q28537826-18762329-B409-43B9-BABB-E907A47EDBC3Q28544718-72A0C187-4663-4BBD-B9D3-6E9AE52F43DEQ29247916-A4EA7233-2384-4E78-8CF4-97AD9D01AE90Q30235089-5FAB2989-1802-4C34-A210-10F70DEEF43EQ30277969-26323699-5FE3-4C99-93B4-10A916DD4432Q33784830-3D4753A5-ACE0-496A-96CA-B768EF783E7CQ33917967-AB3A4E9F-A63A-421A-9945-5207469EFEABQ34342305-37185B2A-14A2-4A82-B5B2-DE75D8BBDED9Q34943114-F2C462DD-69C2-48E9-AE35-128354F6EE88Q35000102-5145A858-251D-49DC-A8D5-0B2C99E7EDBBQ36145491-FE378261-8643-44D1-844F-EACA0A5736E2Q36811351-8DF9F571-651C-45B1-8E3C-EDD91A6C152FQ37095609-BEE72E83-F6BA-46B7-B462-D4AA24E17E1BQ37280079-8E108DCC-4E9C-400D-890F-49ADDD4C41B8Q37389408-16FDC754-7A4C-4EDC-A3A2-1FAA423B3FFDQ38183208-0093DCFF-8A2E-485B-9C9E-D36D1681F015Q38187450-FFB4B48E-F13E-4F8D-BD74-D9709B47C0EEQ38217626-0AA33594-EDF8-426D-92A2-90BCD7CC762CQ38243926-EBBD1007-8CF3-4C62-96A2-9AFC38AA5C76Q38254730-AE98E1CE-CE38-4A9F-B516-209978C275EBQ38360770-971DC2DC-5CBA-49B5-909C-B674D495F307Q38651282-BACD1407-AD44-46BE-847F-E6808F773CC5Q38653000-1EFD988A-C24A-44A3-8A61-A7AED7302F87Q38753644-AC6EA2AD-3FAE-437E-BCFA-0D73B9B96F54Q39037269-336DA3D6-03D9-43D0-80E9-753BBEE9D75CQ39043874-D28456C8-CEBA-44F1-BD83-B4272E6974D8Q39061191-8B399EC1-C962-4470-BCD6-5177F736E725Q39158128-550E5733-392B-4517-A27F-62C8F8215B4BQ47570862-E0D83490-A3CB-4824-AE48-05624321AE2AQ50699986-DE882C8A-BB47-4684-9429-043086BA1840Q53707802-973396D7-08F7-4CF5-A348-90DB3F2BF0BAQ57302643-AF67A9F7-83B8-4977-A7A4-9C12C94779E7
P2860
Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Limited contribution of common ...... ury due to a variety of drugs.
@en
type
label
Limited contribution of common ...... ury due to a variety of drugs.
@en
prefLabel
Limited contribution of common ...... ury due to a variety of drugs.
@en
P2093
P2860
P1476
Limited contribution of common ...... ury due to a variety of drugs.
@en
P2093
Andrew Stolz
Aris Floratos
David B Goldstein
Dongliang Ge
Drug-Induced Liver Injury Network
Herbert Bonkovsky
International Serious Adverse Events Consortium
Itsik Pe'er
P2860
P304
P356
10.1097/FPC.0B013E3283589A76
P577
2012-11-01T00:00:00Z